Inventor

LIU NINGSHU

DE20 patents

⚠️ This page may combine multiple inventors who share the name “LIU NINGSHU”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

LIU NINGSHU

Bayer Pharma AG

Combination of PI3K-inhibitors

Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines for treating lymphomas

Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinations

Combinations of copanlisib with anti-PD-1 antibody

2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides

Combination of PI3K-inhibitors

Compounds

Amido-substituted azole compounds

LIU NINGSHU

Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one

Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines

Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy

(5s,8s)-3-(4′-chlor-3′-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5] dec-3-en-2-one (compound A) for treatment

SCOTT WILLIAM JOHNSTON

Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines

Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines

BAYER IP GMBH

Use of substituted 2, 3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

AVENTIS PHARMA GMBH

Nucleic acid construct for the cell cycle regulated expression of structural genes

VENNEMANN MATTHIAS

Fused pyrimidines